SGR-2921
Near Add Your Location
Accepting patients
SGR-2921
A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- CDC7 Inhibitor
- Phase 1
Accepting patients